Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Alan Taylor

Clinical Nurse Specialist, Home Health Eddystone, PA Physician Assistant

NPI 1104898352 CMS profile 10900775

1510 Chester Pike, Suite 130, Eddystone, PA 19022

Open in the dashboard

General payments

$4,789

182 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alan Taylor of Eddystone, PA is reported in the CMS Open Payments database as having received $4,789 across 182 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,213 44
2024 General $981 42
2023 General $899 42
2022 General $1,670 53
2021 General $27 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alan Taylor
  • Pennsylvania median
  • Middle half of Pennsylvania
  • National median

In program year 2025, general payments to Alan Taylor were reported at $1,213. Among 44,217 Pennsylvania profiles paid that year, the median was $168 and the middle half received between $50 and $597.

Show as a table
Year Alan Taylor Pennsylvania median Middle half National median
2019 $0 $156 $46–$628 $163
2020 $0 $109 $33–$381 $114
2021 $27 $125 $35–$469 $132
2022 $1,670 $136 $40–$499 $149
2023 $899 $147 $46–$523 $160
2024 $981 $156 $46–$568 $164
2025 $1,213 $168 $50–$597 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Mannkind Corporation $1,305 63 payments
  2. Lilly USA, LLC $574 25 payments
  3. Bioventus LLC $492 2 payments
  4. Medtronic, Inc. $421 12 payments
  5. Collegium Pharmaceutical, Inc. $403 19 payments
  6. Novo Nordisk Inc $335 12 payments
  7. Xeris Pharmaceuticals, Inc. $177 8 payments
  8. Boston Scientific Corporation $142 1 payment
  9. Sanofi-Aventis U.S. LLC $104 4 payments
  10. AstraZeneca Pharmaceuticals LP $104 6 payments
  11. Other $731 30 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,306 179 payments
  2. Travel and Lodging $381 1 payment
  3. Gift $59 1 payment
  4. Education $43 1 payment
Products named General payments · program years 2021–2025
  1. AFREZZA $1,305 63 payments
  2. Stimrouter Implantable Kit $492 2 payments
  3. MOUNJARO $443 19 payments
  4. XTAMPZA $403 19 payments
  5. Ozempic $335 12 payments
  6. MINIMED 770G $269 4 payments
  7. TRULICITY $253 11 payments
  8. ZEPBOUND $149 6 payments
  9. RECORLEV $121 5 payments
  10. INPEN SMART INSULIN DELIVERY SYSTEM $111 5 payments
  11. Other $1,305 57 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 73 drugs

Part D claims

4,725

Median for Certified Clinical Nurse Specialist: 344

Drug cost

$670,408

Median for Certified Clinical Nurse Specialist: $20,739

Branded share of claims

26.9%

Median for Certified Clinical Nurse Specialist: 20.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycontin Oxycodone Hcl Brand 176 $292,822
Nucynta Er Tapentadol Hcl Brand 43 $84,701
Xtampza Er Oxycodone Myristate Brand 73 $77,306
Oxycodone Hcl Generic 1,145 $46,329
Fentanyl Generic 161 $25,609
Mounjaro Tirzepatide Brand 20 $22,324
Arexvy Rsvpref3 Antigen/As01e/Pf Brand 70 $20,281
Morphine Sulfate Er Morphine Sulfate Brand 314 $16,085
Hydromorphone Er Hydromorphone Hcl Brand 12 $10,436
Shingrix Varicella-Zoster Ge/As01b/Pf Brand 47 $10,045

The 10 drugs with the highest cost, of 73 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,644 Part D prescribers listed as Certified Clinical Nurse Specialist; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AFREZZA
  • Mannkind Corporation $284
$284 — —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $111
$111 73 —
MOUNJARO
  • Lilly USA, LLC $96
$96 20 —
Ozempic
  • Novo Nordisk Inc $91
$91 — —
RYBELSUS
  • Novo Nordisk Inc $25
$25 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

182 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record